Tatiana Salimova

Tatiana Salimova

Auto-generated profile, based on publicly available information

Tatiana Salimova

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
OGOlga Goronkova
Olga Goronkova
GNGalina Novichkova
Galina Novichkova
TSTatiana Salimova
Tatiana Salimova
IKIrina Kalinina
Irina Kalinina
DBDina Baidildina
Dina Baidildina
AMAlexey Maschan
Alexey Maschan
We compared the efficacy and safety of eltrombopag (ELTR) combined with immunosuppressive therapy (IST) and IST alone in treatment-naïve children with severe (SAA) and very severe (vSAA) aplastic anemia. Ninety-eight pediatric patients were randomized to receive horse antithymocyte globulin (hATG) and cyclosporin A (CsA) with (n = 49) or without (n = 49) ELTR. The primary endpoint was the overall response rate (ORR) at 4 months. After 4 months, nonresponders were crossed over to the alternative group. In all patients, the ORR in ELTR + IST and IST groups was similar (65% vs 53%; P = .218); however, the complete response (CR) rate was significantly higher in the ELTR + IST group (31% vs 12%; P = .027). In severity subgroups, the ORR was 89% vs 57% (P = .028) in favor of IST + ELTR in SAA, but it did not differ in patients with vSAA (52% vs 50%; P = .902). At 6 months after the crossover, 61% of initial ELTR(−) patients achieved a response compared with 17% of initial ELTR(+) patients (P = .016). No significant difference in ELTR + IST and IST groups was observed in the 3-year overall survival (OS) (89% vs 91%; P = .673) or the 3-year event-free survival (EFS) (53% vs 41%; P = .326). There was no unexpected toxicity related to ELTR. Adding ELTR to standard IST was well tolerated and increased the CR rate. The greatest benefit from ELTR combined with IST was observed in patients with SAA but not in those with vSAA. The second course of IST resulted in a high ORR in initial ELTR(−) patients who added ELTR and had limited efficacy among patients who received ELTR upfront. This trial was registered at Clinicaltrials.gov as #NCT03413306.

27 March 2022 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
IKI. I. Kalinina
I. I. Kalinina
DVD. A. Venyov
D. A. Venyov
YOYu. V. Olshanskaya
Yu. V. Olshanskaya
MSM. N. Sadovskaya
M. N. Sadovskaya
OGO. V. Goronkova
O. V. Goronkova
ЮОЮ. В. Ольшанская
Ю. В. Ольшанская
Over the past years, the outcomes of patients with acute myeloid leukemia (AML) have significantly improved due to the use of intensive chemotherapy, more effective supportive therapy, and the availability of allogeneic hematopoietic stem cell transplantation. This article presents the outcomes of children with AML treated in accordance with the AML-MM-2006 protocol. Our study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The study included 233 patients with a median age of 6.5 years (7 days – 18 years) who were stratified into the following risk groups: standard risk, intermediate risk, and high risk. The 5-year event-free survival (EFS) was 0.64 ± 0,14, 0.49 ± 0.05, and 0.43 ± 0.05 for standard-risk (n = 12), intermediate-risk (n = 106), and high-risk (n = 115) patients, respectively (p = 0.14), while the 5-year overall survival (OS) was 1.0 year, 0.7 ± 0.05 and 0.55 ± 0.05, respectively (p = 0.001). The OS in the entire cohort was 0.68 ± 0.032. Factors associated with poor prognosis included hyperleukocytosis, the presence of extramedullary lesions, and age 1 year. The overall survival rates in these patient groups were 0.55 ± 0.08, 0.39 ± 0.09 and 0.49 ± 0.08, respectively. The worst prognosis was for patients with monosomy 7 and t(7;12) whose OS rates were 0.25 ± 0.2 and 0.4 ± 0.2, respectively. For non-responders and patients with relapsed AML, the OS was 0.33 ± 0.08 and 0.54 ± 0.06, respectively. Early death (before remission could be achieved) occurred in 4% of patients, and 3.8% of patients died in first remission. Sixtytwo percent of deceased patients died of disease progression. In the entire cohort of patients, the five-year EFS was 0.53 ± 0.047, the cumulative risk of relapse after 3 years of remission was 40%, the confidence interval was 23–89%.

13 April 2021 in Oncohematology
Verified
Journal Article
Open access
PDF file
AIA. K. Ignatova
A. K. Ignatova
IKI. I. Kalinina
I. I. Kalinina
DVD. A. Venev
D. A. Venev
TST. Yu. Salimova
T. Yu. Salimova
DED. A. Evseev
D. A. Evseev
ЮОЮ. В. Ольшанская
Ю. В. Ольшанская
Background. Extramedullary infiltration (EI) is relatively common in children with acute myeloid leukemia (AML) (up to 20-25 %). However, its clinical and prognostic significance remains poorly understood.Objective: to describe clinical features and to define prognostic significance of EI in children with AML.Materials and methods. The subjects of retrospective observational study were 228 children with de novo AML. The median age was 6.6 years. All of them were treated according to the protocol AML-MM-2006 from April 2007 to June 2018.All patients with EI were divided into three cohorts according to the localization of the lesions: 1) central nervous system (CNS) involvement (CNS group), 2) other localizations apart from CNS (myelosarcomas (MS) group), 3) combined lesions (CNS + MS group).Results. EI was diagnosed in 84 patients (36.84 %) with de novo AML. Among them 47 (55.95 %) had CNS involvement, 20 (23.81 %) had MS, 15 (17.86 %) had both CNS involvement and MS. 5-year overall survival (OS) rate was slightly higher in patients with CNS involvement than in children without EI - 80 ± 12 % vs 71 ± 9 %, p = 0.26, however OS in patients with MS was significantly lower - 45 ± 16 % vs 71 ± 9 %, p 0.001. In addition, OS in high-risk patients according to the protocol AML-MM-2006 who underwent allogenic hematopoietic stem cell transplantation (HSCT) without EI and with MS (± CNS involvement) was similar to OS in main groups - 81 ± 11 % and 42 ± 26 % respectively, p = 0.004. 5-year event-free survival in patients with MS was also lower than in children without EI - 38 ± 16 % vs 51 ± 8 %, p = 0.011.Conclusion. Patients with MS had worse 5-year OS and EFS than children without EI according to our study. Moreover allogenic HSCT conducted in first clinical remission did not improve the survival rate. Neuroleukemia as the only EI was not an unfavorable prognostic factor in our cohort of AML patients and was more often associated with inv(16).

23 September 2018 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
DED. A. Evseev
D. A. Evseev
IKI. I. Kalinina
I. I. Kalinina
NUN. G. Uskova
N. G. Uskova
ASA. E. Samarin
A. E. Samarin
ERE. V. Raykin
E. V. Raykin
AMA. A. Maschan
A. A. Maschan
Langerhans-cell histiocytosis (LCH) is a rare myeloid neoplasia (about 3 cases per 1 000 000 children yearly). Lung involvement is rare, usually as a part of multisystem disease. Clinically these lesions manifest with signs of respiratory insufficiency like dyspnea, cough and desaturation. Imaging shows nodules that are gradually transforming into thick- or thin-walled cysts. Rapture of these cysts leads to the pneumothorax which requires drainage. Our report shows clinical case of use of elective pleurodesis to prevent life-threatening complications of histologically confirmed LCH with lung involvement, which can develop either as a result of the disease or due to chemotherapy.

7 October 2021 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
ESE. V. Suntsova
E. V. Suntsova
AMA. A. Maschan
A. A. Maschan
OMO. N. Mironenko
O. N. Mironenko
ДБД. Д. Байдильдина
Д. Д. Байдильдина
IKI. I. Kalinina
I. I. Kalinina
GNG. A. Novichkova
G. A. Novichkova
Thrombopoietin receptor agonists (TPO-RA) – romiplostim and eltrombopag – changed considerably the therapeutic options for severe persistent and chronic immune thrombocytopenia (ITP). The article presents the results of a retrospective study of TPO-RA efficacy and safety in patients under 18 years of age. The study was approved by the Independent Ethics Committee and Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Sixty-eight children had a total of 89 courses of TPO-RA (44 romiplostim and 45 eltrombopag). Their median age was 6.5 years. The median ITP duration was 15.8 months. All patients received previous ITP therapy (1–6 lines). Before the initiation of TPO-RA, the majority of patients had thrombocytopenia with bleeding. In most cases, the platelet response was achieved within the first 2 months of treatment. The average effective doses of romiplostim and eltrombopag were 10 mg/kg per week and 75 mg per day, respectively. Half of patients in romiplostim group and 62% of patients in eltrombopag group did not require extra therapy. The majority of patients (75.6–81.8%) achieved an overall response, but only near 50% achieved a durable (more than 24 weeks) platelet response. Six patients sustained the response after TPO-RA discontinuation. The most common adverse events (AE) of TPO-RA therapy were transient elevation in hepatic enzymes in eltrombopag group (28.9%) and thrombocytosis (18.2–22.2%) in both groups. In 6 cases the therapy was discontinued due to AEs. Two AEs were serious. Our results demonstrate that TPO-RA could safely increase platelet counts and decrease the risk of spontaneous life-threatening bleeding in nearly half of children with severe persistent and chronic ITP. TPO-RA could help to avoid long-term immunosuppressive therapy and splenectomy or delay them and the ITP remission is possible in some cases.

9 February 2018 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
OGO. V. Goronkova
O. V. Goronkova
IKI. I. Kalinina
I. I. Kalinina
TST. Yu. Salimova
T. Yu. Salimova
ESE. V. Suntsova
E. V. Suntsova
UPU. N. Petrova
U. N. Petrova
AМA. A. Мaschan
A. A. Мaschan
The association of aplastic anemia (AA) with other autoimmune diseases (AID) is rarely described and so far not systematically evaluated. We have analysed the literature data and present our own experience. We assessed the incidence and the outcome of concomitant AID in a retrospective, single-center study of 370 patients with AA treated between 1996 and 2014 with either immunosuppression (296) or hematopoietic stem cell transplantation (74) and a median follow-up time of 7 years (0.5–18). Results: Clinically manifest AID were observed in 10 out of 370 (2.7%) patients. Age at diagnosis of AA was similar in patients without AID compared to patients with AID (median, 10,9 versus 10 years; p 0.05). In 3 patients where the diagnosis of AID was done before AA therapy, response to antithymocyte globulin was good for AA (2 out of 3) but not for AID (0 out of 3). In 7 patients in which AID occurred after first-line therapy, the median time to the AID was 6 months (range 2 months–13.4 years). Response to antithymocyte globulin was good for AA (7 out of 7), but treatment of AID was successful in 43% (3 out of 7) patients. Conclusions: The association of AA with AID in children is very rare. Most cases of AA in association with AID benefitted from IST, but IST was not influence to outcome of concomitant AID.